Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw its share price surge roughly 80% on Thursday after unveiling a transaction in which an affiliate of Apotex will acquire Cumberland's branded pharmaceutical product line for $100 million in cash.
Under the terms disclosed by Cumberland, the sale covers the company's marketed branded pharmaceuticals. The company emphasized that it will keep its pipeline product candidates and maintain majority ownership of Cumberland Emerging Technologies Inc. Management said the shift allows Cumberland to concentrate resources on advancing its development-stage assets, particularly orphan drug programs.
Cumberland's chief executive, A.J. Kazimi, characterized the transaction as a shareholder-value creating move. In a company statement he said:
"This transaction unlocks value for our shareholders and enables us to focus on the large market opportunities associated with our pipeline product candidates."
The Nashville-based specialty pharmaceutical firm is developing ifetroban, a thromboxane antagonist, across multiple clinical programs targeting significant unmet needs. Cumberland reported breakthrough results from a Phase II study of ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy. That program has received Orphan Drug, Rare Pediatric Disease and Fast Track designations from the U.S. Food and Drug Administration.
Separately, Cumberland has completed enrollment in a Phase II clinical study evaluating ifetroban in patients with Systemic Sclerosis; top-line results from that study have not yet been released. A third development program for ifetroban targets patients with Idiopathic Pulmonary Fibrosis, and enrollment for that program is currently underway at medical centers across the United States.
Apotex, described as the largest Canadian-based pharmaceutical company, will fold Cumberland's commercial operations into its U.S. specialty medicines platform as part of the agreement.
The proposed transaction requires authorization and approval by Cumberland's shareholders before it can close.
Implications for Cumberland
The divestiture of marketed brands transfers the company's commercial footprint to Apotex while leaving Cumberland positioned as a development-stage drugmaker focused on orphan and specialty indications. Cumberland's retained pipeline and majority stake in its emerging technologies affiliate will form the basis for its post-transaction strategy.
Market reaction
Investors responded swiftly to the deal announcement, bidding Cumberland's shares sharply higher. The market move reflects investor assessment of the cash consideration and the strategic refocus on higher-growth, development-stage programs.